DKZ: Enzyme Immunoassay, Amphetamine

Product code DKZ, “Enzyme Immunoassay, Amphetamine” in FDA's classification database, is a Class II device type under 21 CFR 862.3100 (amphetamine test system), reviewed by FDA's Clinical Toxicology panel. FDA's 510(k) database lists 225 clearances under DKZ, 47 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
DKZ
Regulation
21 CFR 862.3100
Class
II
Panel
Clinical Toxicology
Clearances
225
Most recent
Oct 30, 2024
Median review, last 2 years
233 days
Third-party review
Eligible
Implant
No

What it covers

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

The identification in 21 CFR 862.3100, amphetamine test system. FDA gives DKZ no definition of its own, so the regulation’s describes it.

Recent clearances

510(k)DeviceApplicantDecisionType
K240670DRI Ecstasy Plus AssayMicrogenics CorporationOct 30, 2024Special
K233019AllTest Multi-Drug Rapid Test Cup; AllTest Multi-Drug Rapid Test Panel; AllTest Multi-Drug Rapid Test Cup Rx; AllTest Multi-Drug Rapid Test Panel RxHangzhou AllTest Biotech Co., Ltd.Dec 13, 2023Traditional
K231137Xenta Drug Screen Cup, Xenta Drug Screen DipcardXenta Biomedical Science Co., Ltd.May 19, 2023Traditional
K200363Quidel Triage® TOX Drug Screen, 94600Quidel Cardiovascular, Inc.Mar 11, 2020Special
K191099Atlas Multi-Drugs Screening Test Cup, Atlas Multi-Drugs Screening Test PanelAtlas MedicalOct 3, 2019Traditional
K182719Quidel Triage TOX Drug Screen, 94600; Quidel Triage® MeterProQuidel Cardiovascular, Inc.Jun 19, 2019Traditional
K182738Single and Multi-Drug Rapid Test Panel With Adulteration (Urine), Single and Multi-Drug Rapid Test Panel (Urine), Single and Multi-Drug Rapid Test Cup With Adulteration (Urine), Single and Multi-Drug Rapid Test Cup (Urine), Single Drug Rapid Test Dipstick (Urine), Single and Multi-Drug Home Rapid Test Panel (Urine), Single and Multi-Drug Home Rapid Test Cup (Urine), Single Drug Home Rapid Test Dipstick (Urine)Hangzhou AllTest Biotech Co., Ltd.Mar 27, 2019Traditional
K180879BIO-VENTURE Rapid Multi-Drug Test Easy Cup for OTC Use, BIO-VENTURE Rapid Multi-Drug Test Split Key Cup for OTC Use, BIO-VENTURE Rapid Multi-Drug Test Easy Cup for Rx Use, BIO-VENTURE Rapid Multi-Drug Test Split Key Cup for Rx UseShanghai Venture Bio-Tech Co., Ltd.Dec 14, 2018Traditional
K181945QuickScreen Pro Multi Drug Screening Test, Model 9395ZPhamatech, Inc.Oct 18, 2018Traditional
K173303INSTANT-VIEW plus Multi-Drug of Abuse Urine Test - Simple Cup (OTC Use), INSTANT-VIEW plus Multi-Drug Urine Test - Simple Cup (Prescription Use)Alfa Scientific Designs, Inc.Feb 23, 2018Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 225 with a free account)

Clearances by year

47 DKZ 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
20241233
2023255
2020126
20193180
20183128
20165215
20155107
20148128
20138103
2012555
20116123

Who submits

28 applicants cleared a DKZ device since 2011. 79% of the clearances went to applicants in United States, then China (17%), United Kingdom (2%) and Jordan (2%). By type: Traditional 79%, Special 19% and Abbreviated 2%.

ApplicantClearances since 2011
Ucp Biosciences, Inc.7
Guangzhou Wondfo Biotech Co., Ltd.6
Alfa Scientific Designs, Inc.3
Chemtron Biotech, Inc.3
Co-Innovation Biotech Co., Ltd.2
Hangzhou AllTest Biotech Co., Ltd.2
Phamatech, Inc.2
Quidel Cardiovascular, Inc.2

How FDA classifies it

Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing.

From 21 CFR 862.3100. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 862.3100 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent DKZ clearances declared.

Ask about DKZ

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about DKZ

What is FDA product code DKZ?

Product code DKZ, “Enzyme Immunoassay, Amphetamine” in FDA's classification database, is a Class II device type under 21 CFR 862.3100 (amphetamine test system), reviewed by FDA's Clinical Toxicology panel. FDA's 510(k) database lists 225 clearances under DKZ, 47 of them since 2011.

How many 510(k) clearances are there under DKZ?

FDA’s 510(k) database listed 225 clearances under DKZ as of Oct 29, 2026, 47 of them decided since 2011; the most recent decision was Oct 30, 2024. The Predicate Finder searches the live database.

How long does FDA take to clear a DKZ 510(k)?

For the 1 DKZ clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 233 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most DKZ clearances?

Since 2011: Ucp Biosciences, Inc. (7), Guangzhou Wondfo Biotech Co., Ltd. (6), Alfa Scientific Designs, Inc. (3), Chemtron Biotech, Inc. (3) and Co-Innovation Biotech Co., Ltd. (2). 28 applicants have cleared a DKZ device in that time.

Sources

  1. FDA product classification: DKZ · Product Classification database
  2. 21 CFR 862.3100: Amphetamine test system · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for DKZ · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow DKZGet an email when FDA clears, recalls or publishes guidance for DKZ devices.

Know what FDA already cleared.